Abstract:Background: Minoxidil solution has routinely been used for decades for the treatment of androgenic alopecia. Central serous chorioretinopathy (CSCR) is a rare side-effect noted following prolonged topical minoxidil therapy for androgenic alopecia. In this report, we describe a case of a 41-year-old young man who developed CSCR following prolonged therapy with topical Minoxidil solution and was treated with oral eplerenone. Case presentation: A 41-year-old male presented to the retina clinic with complaints of seeing a black spot, blurred vision and metamorphopsia involving the right eye for the past 4 months. He was on treatment for androgenic alopecia with topical 5% Minoxidil application on scalp two times a day. He noticed the symptoms 8 months after starting the treatment and had stopped the medication since the past 2 months. On examination, best-corrected visual acuity was 20/20 in both eyes. Fundoscopic examination of the right eye with +78D lens on slit lamp revealed the presence of subretinal fluid and few focal spots of retinal pigment epithelial alterations. Optical coherence tomography scan evaluation showed the presence of subretinal fluid (SRF) and pachychoroid supporting the diagnosis of CSCR. Indocyanine green angiography revealed dilated hyperpermeable choroidal vasculature on the nasal side of the fovea in the early and later phases of the angiogram. The patient was diagnosed with CSCR as a possible consequence of the topical minoxidil solution. Patient was asked to avoid future use of Minoxidil and was started on oral eplerenone therapy 50 mg/day for 4 consecutive weeks. One month later, there was complete resolution of his symptoms and SRF. At the final follow-up visit, 2 months after starting the therapy, there was no recurrence of SRF. Conclusion: CSCR is a rare side-effect noted following prolonged topical minoxidil therapy for androgenic alopecia. While we found oral eplerenone to be safe and effective, further studies would be required before it can be routinely used in the population.

Topical Minoxidil Overdose in a Young Man With Androgenetic Alopecia: A Case Report

A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure

A Case of Contact Allergic Dermatitis to Topical Minoxidil

The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia

Topical minoxidil reported hair discoloration: a cross-sectional study

Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose

Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double‐blind, placebo‐controlled, phase 1B clinical trial

Allergic contact dermatitis to topical minoxidil solution: etiology and treatment

Clinical efficacy and safety of low‐dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: A randomized controlled trial

A Comparative Study on the Efficacy and Safety of 10% Topical Minoxidil versus 5% Topical Minoxidil in the Treatment of Male Pattern Hair Loss

Safety of low‐dose oral minoxidil treatment for hair loss. A systematic review and pooled‐analysis of individual patient data

Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review

Role of low dose oral minoxidil in the treatment of hair loss: A review

Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review

Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short-term use of topical minoxidil solution

Patient perspectives on topical minoxidil for hair loss: a survey-based study from the University of Michigan Alopecia Clinic

Oral minoxidil use in androgenetic alopecia and telogen effluvium

Evaluation of the Safety and Effectiveness of Oral Minoxidil in Children: A Systematic Review

Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report

Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions

Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia